Krystal Biotech Income Statement (2016-2026) | KRYS

Income Statement Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
8.56M42.14M45.30M70.30M83.84M91.11M88.18M96.00M97.80M107.10M116.36M
Cost of Revenue (Quarter)
0.22M2.87M2.42M6.01M6.68M4.95M5.03M7.17M4.26M6.59M6.32M
Gross Profit (Quarter)
8.33M39.27M42.88M64.29M77.16M86.17M83.16M88.83M93.54M100.51M110.03M
Operating items
Research & Development (Quarter)
6.59M6.08M9.01M9.31M10.89M11.52M10.74M12.29M12.14M10.63M11.37M10.96M15.58M13.51M13.53M14.26M14.41M14.59M14.79M15.33M
Selling, General & Administrative (Quarter)
9.80M9.57M12.87M15.91M17.86M19.93M24.03M24.04M25.90M23.70M24.65M26.06M27.63M28.67M31.29M32.65M35.16M37.58M41.45M41.01M
Restructuring Costs (Quarter)
25.00M12.50M12.50M37.50M12.50M37.50M12.50M
Other Operating Expenses (Quarter)
-12.50M100.00M2.42M-18.99M-37.50M5.03M7.17M4.26M6.59M6.32M
Operating Expenses (Quarter)
16.39M15.65M21.88M50.22M28.75M31.45M34.77M48.82M38.05M34.55M38.90M51.93M61.72M61.37M49.76M51.93M56.73M56.43M62.84M62.67M
Operating Income (Quarter)
-16.39M-15.65M-21.88M-50.22M-28.75M-31.45M-34.77M-48.82M-38.05M-25.99M3.25M-6.68M8.57M22.47M41.38M36.25M39.31M41.37M44.27M53.69M
EBIT (Quarter)
-16.39M-15.65M-21.88M-50.22M-28.75M-31.45M-34.77M-48.82M-38.05M-25.99M3.25M-6.68M8.57M22.47M41.38M36.25M39.31M41.37M44.27M53.69M
Non-operating items
Interest & Investment Income (Quarter)
0.03M0.06M0.07M0.26M0.65M1.60M2.72M3.53M4.84M6.74M7.41M7.62M7.48M7.30M7.24M7.34M7.47M6.59M6.86M7.75M
Non Operating Income (Quarter)
Net income details
EBT (Quarter)
-16.36M-15.59M-21.81M-49.97M-28.11M-29.85M-32.05M-45.30M-33.21M80.75M10.66M0.93M16.05M29.77M48.61M43.60M46.77M47.97M51.13M61.44M
Tax Provisions (Quarter)
1.97M0.48M2.59M3.10M7.86M8.40M-31.40M-0.27M5.51M
Profit After Tax (Quarter)
-16.36M-15.59M-21.81M-49.97M-28.11M-29.85M-32.05M-45.30M-33.21M80.75M8.69M0.93M15.57M27.18M45.48M35.73M38.33M79.36M51.40M55.93M
Income from Continuing Operations (Quarter)
-16.36M-15.59M-21.81M-49.97M-28.11M-29.85M-32.05M-45.30M-33.21M80.75M8.69M0.93M15.57M27.18M45.51M35.73M38.38M79.36M51.40M55.93M
Consolidated Net Income (Quarter)
-16.36M-15.59M-21.81M-49.97M-28.11M-29.85M-32.05M-45.30M-33.21M80.75M8.69M0.93M15.57M27.18M45.51M35.73M38.38M79.36M51.40M55.93M
Income towards Parent Company (Quarter)
-16.36M-15.59M-21.81M-49.97M-28.11M-29.85M-32.05M-45.30M-33.21M80.75M8.69M0.93M15.57M27.18M45.51M35.73M38.38M79.36M51.40M55.93M
Net Income towards Common Stockholders (Quarter)
-16.36M-15.59M-21.81M-49.97M-28.11M-29.85M-32.05M-45.30M-33.21M80.75M8.69M0.93M15.57M27.18M45.51M35.73M38.38M79.36M51.40M55.93M
Additional items
EPS (Basic) (Quarter)
-0.74-0.70-0.95-1.99-1.10-1.17-1.25-1.76-1.252.880.320.030.540.951.591.241.332.741.771.91
EPS (Weighted Average and Diluted) (Quarter)
-0.74-0.70-0.95-1.99-1.10-1.17-1.25-1.76-1.252.790.310.030.530.911.531.201.292.661.701.83
Shares Outstanding (Weighted Average) (Quarter)
21.73M22.21M22.20M25.11M25.55M25.62M25.49M25.71M26.66M28.04M27.15M28.30M28.45M28.54M28.59M28.82M28.86M28.95M28.94M29.29M
Shares Outstanding (Diluted Average) (Quarter)
21.73M22.21M22.20M25.11M25.33M25.62M25.49M25.71M26.19M28.89M27.75M29.29M29.50M29.67M29.74M29.87M29.75M29.83M29.95M30.51M
EBITDA (Quarter)
-16.39M-15.58M-21.95M-51.00M-28.46M-29.78M-31.30M-44.72M-33.29M80.60M9.71M-0.01M15.23M29.33M43.78M36.31M39.10M79.31M51.44M53.17M
Interest Expenses (Quarter)
Tax Rate (Quarter)
18.44%2.97%8.70%6.37%18.04%17.96%-65.46%-0.53%8.97%